Influenza A virus hemagglutinin, nucleoprotein, and matrix protein 2 (HA/NP/M2)

This target represents a multi-antigen combination consisting of three critical proteins from the Influenza A virus: Hemagglutinin (HA), Nucleoprotein (NP), and Matrix protein 2 (M2). This specific grouping is primarily utilized in the development of universal or broad-spectrum influenza vaccines, such as mRNA-based or viral-vectored candidates, designed to provide protection beyond strain-specific seasonal immunity [1, 3]. Hemagglutinin is the primary surface glycoprotein responsible for binding to host sialic acid receptors and mediating membrane fusion, making it the central target for neutralizing antibodies [7, 9]. Nucleoprotein is a highly conserved internal protein that coats the viral RNA segments and is a dominant target for cross-reactive cytotoxic T-lymphocyte (CTL) responses, which can clear infected cells across different viral subtypes [2, 13]. Matrix protein 2 is an ion channel essential for viral uncoating during entry and for viral budding; its highly conserved ectodomain (M2e) is a target for broadly reactive, non-neutralizing antibodies that mediate protection through Fc-receptor-dependent mechanisms [10, 14]. By combining these antigens, therapeutic strategies aim to elicit a robust, dual-arm immune response—humoral and cellular—to mitigate the impact of antigenic drift and provide a more durable defense against both seasonal and pandemic influenza threats [3, 5].

Other names

Influenza A antigensHA-NP-M2 complexUniversal influenza vaccine antigensFlu A HA/NP/M2Conserved influenza antigens

Induction of broad-spectrum humoral and cellular immune responses; Hemagglutinin (HA) mediates viral attachment and entry, Nucleoprotein (NP) facilitates viral RNA encapsidation and serves as a major T-cell target, and Matrix protein 2 (M2) acts as a proton channel for viral uncoating.